Literature DB >> 1057843

Atypical progressive multifocal leukoencephalopathy with plasma-cell infiltrates.

E P Richardson, P C Johnson.   

Abstract

In rare cases of progressive multifocal leukoencephalopathy (PML) the lesions are atypical in that the characteristic alteration of oligodendrocytic nuclei is infrequent or absent, and the demyelinated foci contain mononuclear inflammatory infiltrates including numerous plasma cells. Otherwise these cases, both as to the topographic features of the lesions, and the background of chronic lymphoproliferative or myeloproliferative disease or immunosuppressive treatment, conform to the usual pattern. In the case here reported, that of a 54-year-old man receiving immunosuppressive drugs for chronic polymyositis, electron microscopy showed papovavirions in astrocytic nuclei and fluorescent antibody studies indicated that these represented JC virus. In this and the 3 previously reported similar cases of atypical PML, the neurologic illness was less devastating than generally occurs in classic PML. Possibly these cases represent instances of unusually strong host-resistance against the disease.

Entities:  

Mesh:

Year:  1975        PMID: 1057843     DOI: 10.1007/978-3-662-08456-4_43

Source DB:  PubMed          Journal:  Acta Neuropathol Suppl        ISSN: 0065-1435


  9 in total

1.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

2.  Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells.

Authors:  Christian Wüthrich; Santosh Kesari; Woong-Ki Kim; Kenneth Williams; Rebecca Gelman; Derek Elmeric; Umberto De Girolami; Jeffrey T Joseph; Tessa Hedley-Whyte; Igor J Koralnik
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

3.  Morphological demonstration of the first phase of polyomavirus replication in oligodendroglia cells of human brain in progressive multifocal leukoencephalopathy (PML).

Authors:  M Mázló; I Tariska
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

4.  Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)?

Authors:  M Mázló; I Tariska
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

Review 5.  Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature.

Authors:  R W von Einsiedel; T D Fife; A J Aksamit; M E Cornford; D L Secor; U Tomiyasu; H H Itabashi; H V Vinters
Journal:  J Neurol       Date:  1993-07       Impact factor: 4.849

6.  Differential distribution of the JC virus receptor-type sialic acid in normal human tissues.

Authors:  Sylvia Eash; Rosemarie Tavares; Edward G Stopa; Scott H Robbins; Laurent Brossay; Walter J Atwood
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 7.  Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  E O Major; K Amemiya; C S Tornatore; S A Houff; J R Berger
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

8.  Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Imke Metz; Ernst-Wilhelm Radue; Agustin Oterino; Tania Kümpfel; Heinz Wiendl; Sven Schippling; Jens Kuhle; Mohammad Ali Sahraian; Francoise Gray; Veronika Jakl; Darius Häusler; Wolfgang Brück
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

9.  Brain Biopsy Is More Reliable than the DNA test for JC Virus in Cerebrospinal Fluid for the Diagnosis of Progressive Multifocal Leukoencephalopathy.

Authors:  Junji Ikeda; Akira Matsushima; Wataru Ishii; Tetuya Goto; Kenta Takahashi; Kazuo Nakamichi; Masayuki Saijo; Yoshiki Sekijima; Shu-Ichi Ikeda
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.